Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:ONTX
- CUSIP: N/A
- Web: www.onconova.com
Capitalization:- Market Cap: $17.04 million
- Outstanding Shares: 9,851,000
Average Prices:- 50 Day Moving Avg: $1.73
- 200 Day Moving Avg: $2.16
- 52 Week Range: $1.50 - $3.88
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.82
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.36 million
- Price / Sales: 7.22
- Book Value: ($0.04) per share
- Price / Book: -43.25
Profitability:- EBIDTA: ($22,150,000.00)
- Net Margins: -762.13%
- Return on Equity: -558.97%
- Return on Assets: -85.62%
Debt:- Current Ratio: 1.62%
- Quick Ratio: 1.62%
Misc:- Average Volume: 38,420 shs.
- Beta: 0.08
- Short Ratio: 15.94
Frequently Asked Questions for Onconova Therapeutics (NASDAQ:ONTX)
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics shares reverse split before market open on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its earnings results on Monday, August, 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.43. The company earned $0.32 million during the quarter, compared to the consensus estimate of $0.25 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 762.13%. View Onconova Therapeutics' Earnings History.
When will Onconova Therapeutics make its next earnings announcement?
Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?
3 brokerages have issued 1-year target prices for Onconova Therapeutics' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Onconova Therapeutics' share price to reach $8.00 in the next year. View Analyst Ratings for Onconova Therapeutics.
Who are some of Onconova Therapeutics' key competitors?
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Michael M. B Hoffman, Chairman of the Board
- Ramesh Kumar Ph.D., President, Chief Executive Officer, Director
- Mark Guerin, Chief Financial Officer
- Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer
- Manoj Maniar Ph.D., Senior Vice President - Product Development
- Henry S. Bienen Ph.D., Director
- Jerome E. Groopman M.D., Director
- Viren Mehta Ph.D., Director
- E. Premkumar Reddy Ph.D., Director
- Jack E. Stover CPA, Director
Who owns Onconova Therapeutics stock?
Onconova Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Tyndall Capital Partners L P (10.51%) and Vanguard Group Inc. (0.93%). Company insiders that own Onconova Therapeutics stock include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.
Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?
Onconova Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Tyndall Capital Partners L P and Vanguard Group Inc.. Company insiders that have bought Onconova Therapeutics stock in the last two years include E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.
How do I buy Onconova Therapeutics stock?
Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of Onconova Therapeutics stock can currently be purchased for approximately $1.73.
MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Onconova Therapeutics (NASDAQ:ONTX)Earnings History by Quarter for Onconova Therapeutics (NASDAQ ONTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | ($0.73) | | | | | N/A |  |
| 8/14/2017 | Q2 2017 | ($0.72) | ($0.29) | $0.25 million | $0.32 million | View | N/A | |
| 5/15/2017 | Q1 2017 | ($0.96) | ($1.23) | | $0.21 million | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.82) | ($0.29) | $1.60 million | $1.70 million | View | N/A | |
| 8/15/2016 | Q2 | | ($1.96) | | $2.25 million | View | N/A | |
| 5/11/2016 | Q1 | ($0.19) | ($0.27) | $1.34 million | $1.47 million | View | N/A | |
| 3/28/2016 | Q4 | ($0.27) | $0.18 | | $9.60 million | View | N/A | |
| 11/11/2015 | Q3 | ($0.32) | ($0.26) | $0.11 million | $1.62 million | View | N/A | |
| 8/13/2015 | Q2 | ($0.56) | ($0.41) | $0.11 million | $0.12 million | View | N/A | |
| 5/14/2015 | Q1 | ($0.63) | ($0.57) | $0.11 million | $0.11 million | View | N/A | |
| 3/26/2015 | | ($0.71) | ($0.62) | | $0.11 million | View | N/A | |
| 11/13/2014 | | ($0.78) | ($0.69) | | $0.11 million | View | N/A | |
| 8/13/2014 | | ($0.89) | ($0.77) | $0.56 million | $0.13 million | View | N/A | |
| 5/12/2014 | | ($0.78) | ($0.87) | $1.32 million | $0.45 million | View | N/A | |
| 3/10/2014 | Q4 13 | ($1.07) | ($0.68) | $1.07 million | $1.93 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.66) | ($1.34) | $1.07 million | $1.12 million | View | Listen | |
| 9/6/2013 | Q213 | | ($5.21) | $0.22 million | $0.59 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.72) | ($0.72) | ($0.72) |
| Q3 2017 | 1 | ($0.73) | ($0.73) | ($0.73) |
| Q4 2017 | 1 | ($0.74) | ($0.74) | ($0.74) |
(Data provided by Zacks Investment Research)
Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Onconova Therapeutics (NASDAQ:ONTX)Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 26.83%
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/26/2017 | E Premkumar Reddy | Director | Buy | 119,048 | $2.10 | $250,000.80 | |
| 4/26/2017 | Mark Patrick Guerin | CFO | Buy | 1,429 | $2.10 | $3,000.90 | |
| 4/26/2017 | Ramesh Kumar | Insider | Buy | 23,810 | $2.10 | $50,001.00 | |
| 2/21/2014 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 143,480 | $8.47 | $1,215,275.60 | |
| 2/10/2014 | Ramesh Kumar | CEO | Sell | 33,543 | $15.07 | $505,493.01 | |
| 2/3/2014 | Ramesh Kumar | CEO | Sell | 60,000 | $15.05 | $903,000.00 | |
| 1/27/2014 | Michael Hoffman | Director | Buy | 57,295 | $11.92 | $682,956.40 | |
| 11/22/2013 | Michael Hoffman | Director | Buy | 5,000 | $14.39 | $71,950.00 | |
| 11/18/2013 | E Premkumar Reddy | Director | Buy | 5,000 | $12.10 | $60,500.00 | |
| 11/15/2013 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 19,700 | $11.99 | $236,203.00 | |
| 11/15/2013 | Henry Bienen | Director | Buy | 1,400 | $12.17 | $17,038.00 | |
| 11/15/2013 | Ramesh Kumar | CEO | Buy | 1,100 | $12.02 | $13,222.00 | |
| 7/30/2013 | & Jane Hoffman 2013 De Michael | Major Shareholder | Buy | 1,000,000 | $15.00 | $15,000,000.00 | |
| 7/30/2013 | Ramesh Kumar | CEO | Buy | 6,667 | $15.00 | $100,005.00 | |
| 7/30/2013 | Thomas J Mckearn | Insider | Buy | 3,333 | $15.00 | $49,995.00 | |
| 7/30/2013 | Viren Mehta | Director | Buy | 16,667 | $15.00 | $250,005.00 | |
| 7/25/2013 | E Premkumar Reddy | Director | Buy | 1,000 | $22.72 | $22,720.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Onconova Therapeutics (NASDAQ:ONTX)
Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
| Source: |
|
| Date | Headline |
|---|
 | Cellectar Biosciences (CLRB) Reports Strategic Collaboration with Onconova Therapeutics (ONTX) to Develop New ... - StreetInsider.com
www.streetinsider.com - September 22 at 7:31 AM |
 | Head-To-Head Survey: Onconova Therapeutics (ONTX) versus Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - September 15 at 10:20 AM |
| ChemoCentryx (CCXI) & Onconova Therapeutics (ONTX) Financial Contrast
www.americanbankingnews.com - September 11 at 8:18 PM |
 | Onconova Therapeutics to Participate in Two Investor Conferences in September
finance.yahoo.com - September 6 at 7:14 AM |
| Onconova Therapeutics, Inc. (ONTX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - September 2 at 7:32 PM |
 | Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 17 at 6:35 AM |
| Edited Transcript of ONTX earnings conference call or presentation 15-Aug-17 1:00pm GMT
finance.yahoo.com - August 17 at 6:35 AM |
| Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results
finance.yahoo.com - August 16 at 6:31 AM |
| Maxim Group Analysts Give Onconova Therapeutics, Inc. (ONTX) a $6.00 Price Target
www.americanbankingnews.com - August 15 at 3:10 PM |
| Onconova Therapeutics, Inc. (ONTX) Announces Earnings Results, Beats Expectations By $0.43 EPS
www.americanbankingnews.com - August 15 at 1:10 PM |
| Onconova Therapeutics Inc (NASDAQ:ONTX) to Release Earnings on Monday
www.americanbankingnews.com - August 11 at 8:32 PM |
| Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 6:06 AM |
| Onconova Therapeutics, Inc. (NASDAQ:ONTX) Given "Buy" Rating at Dawson James
www.americanbankingnews.com - July 30 at 10:36 AM |
| Equities Analysts Set Expectations for Onconova Therapeutics, Inc.'s Q2 2017 Earnings (NASDAQ:ONTX)
www.americanbankingnews.com - July 28 at 9:49 AM |
| Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating ... - GlobeNewswire (press release)
globenewswire.com - July 26 at 6:07 AM |
| Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
finance.yahoo.com - July 26 at 6:07 AM |
| Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
finance.yahoo.com - July 26 at 6:07 AM |
| Zacks: Onconova Therapeutics, Inc. (NASDAQ:ONTX) Given $5.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - July 12 at 12:55 PM |
| Onconova Therapeutics (ONTX) Presents Rigosertib Data at EHA
www.streetinsider.com - June 27 at 7:08 PM |
| Onconova Therapeutics, Inc. (ONTX) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 27 at 9:06 AM |
| Onconova Therapeutics (ONTX) Presents Rigosertib Data at EHA - StreetInsider.com
www.streetinsider.com - June 27 at 6:56 AM |
| Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid
finance.yahoo.com - June 27 at 6:56 AM |
| Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 8:00 PM |
 | Onconova Therapeutics to Present at the BIO International Convention
feeds.benzinga.com - June 13 at 8:52 AM |
| Zacks: Onconova Therapeutics, Inc. (ONTX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 12 at 8:38 AM |
| Onconova Therapeutics Inc (ONTX) Given a $6.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - June 7 at 4:50 PM |
 | UPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results - MarketWatch
www.marketwatch.com - June 6 at 8:28 AM |
| Onconova Therapeutics (ONTX) Reports Positive Phase 2 Data in Rigosertib Treated Patients with Second-line ... - StreetInsider.com
www.streetinsider.com - June 6 at 8:28 AM |
| Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 5 at 7:39 PM |
| UPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results
finance.yahoo.com - June 5 at 7:39 PM |
| Zacks: Onconova Therapeutics Inc (ONTX) Given Average Recommendation of "" by Analysts
www.americanbankingnews.com - May 24 at 4:10 PM |
| Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association
finance.yahoo.com - May 22 at 9:45 AM |
| Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 19 at 11:49 AM |
| Edited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT
finance.yahoo.com - May 16 at 6:46 PM |
| Onconova Therapeutics Inc (ONTX) Releases Quarterly Earnings Results, Misses Expectations By $0.27 EPS
www.americanbankingnews.com - May 16 at 6:14 PM |
| Onconova Therapeutics Inc (ONTX) PT Set at $6.00 by Maxim Group
www.americanbankingnews.com - May 15 at 3:14 PM |
| Investor Network: Onconova Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 9:59 AM |
| Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 9:59 AM |
 | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 5 at 7:19 PM |
| Onconova Therapeutics Inc (ONTX) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 5 at 2:28 PM |
| Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 7:13 PM |
| Onconova Therapeutics (ONTX) Given Daily Media Sentiment Score of 0.17
www.americanbankingnews.com - May 4 at 11:17 AM |
| Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes - Yahoo Finance
finance.yahoo.com - May 1 at 12:04 PM |
| Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes
finance.yahoo.com - May 1 at 12:04 PM |
 | Bucks County biopharm firm closes $5.2M stock sale
www.bizjournals.com - April 29 at 7:28 PM |
| Ramesh Kumar Acquires 23,810 Shares of Onconova Therapeutics Inc (ONTX) Stock
www.americanbankingnews.com - April 28 at 7:28 PM |
| E Premkumar Reddy Purchases 119,048 Shares of Onconova Therapeutics Inc (ONTX) Stock
www.americanbankingnews.com - April 28 at 7:27 PM |
| Laidlaw Initiates Coverage on Onconova Therapeutics Inc (ONTX)
www.americanbankingnews.com - April 27 at 10:12 PM |
| Onconova Therapeutics Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - April 27 at 7:30 PM |
| Onconova Therapeutics (ONTX) Earning Somewhat Negative Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 27 at 5:04 PM |
Onconova Therapeutics (ONTX) Chart for Tuesday, September, 26, 2017
